TRANSMEDICS GROUP INC (NASDAQ:TMDX) stands out as a high-growth momentum candidate with a solid technical setup. The company, specializing in organ transplant technology, has demonstrated strong earnings and revenue growth while presenting a favorable chart pattern for potential breakout traders.
Growth Momentum Highlights
Exceptional EPS Growth: TMDX reported a staggering 500% year-over-year EPS growth (TTM), with recent quarterly growth rates of 100% (Q2Q) and 58.3% (Q-1).
Revenue Expansion: Sales grew 48.2% in the most recent quarter, following prior quarters with increases of 49.8% and 63.7%.
Profit Margin Improvement: The latest quarter’s profit margin reached 17.9%, up from 5.6% in the prior quarter, indicating expanding profitability.
Analyst Optimism: EPS estimates for next year have been revised upward by 23.5% over the past three months, reflecting improving sentiment.
Technical Strength & Setup
Technical Rating (7/10): TMDX maintains a positive long-term trend, outperforming 89% of healthcare equipment peers.
Setup Quality (7/10): The stock is consolidating after recent gains, with reduced volatility and clear support near $123.94.
Key Levels: Resistance is seen between $129.48-$131.55, with a potential breakout above $131.56 offering an entry point. A stop-loss could be placed below $123.55.